AU2001253568A1 - Lipopolysaccharide-conjugate vaccine for sepsis treatment - Google Patents

Lipopolysaccharide-conjugate vaccine for sepsis treatment

Info

Publication number
AU2001253568A1
AU2001253568A1 AU2001253568A AU5356801A AU2001253568A1 AU 2001253568 A1 AU2001253568 A1 AU 2001253568A1 AU 2001253568 A AU2001253568 A AU 2001253568A AU 5356801 A AU5356801 A AU 5356801A AU 2001253568 A1 AU2001253568 A1 AU 2001253568A1
Authority
AU
Australia
Prior art keywords
lipopolysaccharide
conjugate vaccine
sepsis treatment
sepsis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253568A
Inventor
Dan C. Deborde
Gary L. Gustafson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EndoBiologics Inc
Original Assignee
DAN C DEBORDE
GARY L GUSTAFSON
EndoBiologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26893115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001253568(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by DAN C DEBORDE, GARY L GUSTAFSON, EndoBiologics Inc filed Critical DAN C DEBORDE
Publication of AU2001253568A1 publication Critical patent/AU2001253568A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2001253568A 2000-04-18 2001-04-17 Lipopolysaccharide-conjugate vaccine for sepsis treatment Abandoned AU2001253568A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19773900P 2000-04-18 2000-04-18
US60/197,739 2000-04-18
US23187500P 2000-09-12 2000-09-12
US60/231,875 2000-09-12
PCT/US2001/012417 WO2001078787A2 (en) 2000-04-18 2001-04-17 Lipopolysaccharide-conjugate vaccine for sepsis treatment

Publications (1)

Publication Number Publication Date
AU2001253568A1 true AU2001253568A1 (en) 2001-10-30

Family

ID=26893115

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253568A Abandoned AU2001253568A1 (en) 2000-04-18 2001-04-17 Lipopolysaccharide-conjugate vaccine for sepsis treatment

Country Status (6)

Country Link
US (1) US7014857B2 (en)
EP (1) EP1278548A2 (en)
JP (1) JP2004515450A (en)
AU (1) AU2001253568A1 (en)
CA (1) CA2406229C (en)
WO (1) WO2001078787A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7749511B2 (en) * 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
ES2320334T3 (en) * 2002-02-22 2009-05-21 National Research Council Of Canada USE OF FATTY ACID ANALOGS FOR THE TREATMENT AND / OR PREVENTION OF SKIN PROLIFERATIVE DISEASES.
US20060233776A1 (en) * 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
EP1713508A2 (en) * 2004-01-29 2006-10-25 Biosynexus Incorporated Use of amino-oxy functional groups in the preparation of vaccine conjugates
CA2630404C (en) 2005-11-23 2015-04-14 National Research Council Of Canada Method for de-esterification of the lipopolysaccharide layer of neisseria meningitidis and mannheimia haemolytica
WO2011017101A2 (en) 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
WO2011084705A2 (en) 2009-12-17 2011-07-14 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
WO2013038375A2 (en) * 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
WO2014111516A1 (en) 2013-01-17 2014-07-24 Arsanis Biosciences Gmbh Mdr e. coli specific antibody
AR109621A1 (en) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc FORMULATIONS OF VACCINES AGAINST GLUCOCONJUGADOS OF EXPEC
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK163176C (en) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst POISONOUS CONJUGATE VACCINE AGAINST INFECTIONS OF PSEUDOMONA'S AERUGINOSA AND ESCHERICHIA COLI BACTERIES, METHOD OF PRODUCING IT AND USING THE VACCINE
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5370872A (en) * 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
WO1993013797A2 (en) * 1992-01-16 1993-07-22 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Detoxified lps-cholera toxin conjugate vaccine for prevention of cholera
US5736146A (en) * 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
PT658118E (en) * 1992-08-31 2002-05-31 Baxter Healthcare Sa VACCINES AGAINST NEISSERIA MENINGITIDIS OF GROUP C
US5573916A (en) * 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
US6645503B1 (en) * 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
ES2320334T3 (en) * 2002-02-22 2009-05-21 National Research Council Of Canada USE OF FATTY ACID ANALOGS FOR THE TREATMENT AND / OR PREVENTION OF SKIN PROLIFERATIVE DISEASES.

Also Published As

Publication number Publication date
CA2406229A1 (en) 2001-10-25
WO2001078787A2 (en) 2001-10-25
JP2004515450A (en) 2004-05-27
CA2406229C (en) 2010-09-07
US7014857B2 (en) 2006-03-21
EP1278548A2 (en) 2003-01-29
US20030138448A1 (en) 2003-07-24
WO2001078787A3 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
AU2002223827A1 (en) Well treatment
AU2002218462A1 (en) Thermal treatment system
AU2002222853A1 (en) Therapeutic compounds
AU2001283549A1 (en) Software-to-hardware compiler
AU2001253265A1 (en) Oral treatment systems
EP1195130A3 (en) Endoscope apparatus
EG25829A (en) Novel treatment
AU2001239547A1 (en) Purifying device
AU2001253568A1 (en) Lipopolysaccharide-conjugate vaccine for sepsis treatment
GB0030845D0 (en) Novel treatment
AU2371201A (en) Endoscope
AU2001240791A1 (en) Sequence
AU2001220281A1 (en) Rollerboard for road-skiing
AU2002225327A1 (en) Apparatus for aesthetic treatment
AU2002221760A1 (en) Vaccine for treating allergy
AU2001267769A1 (en) Process
GB0029125D0 (en) Novel treatment
AU2001292897A1 (en) Novel therapy
GB0031321D0 (en) Treatment
AU2001241913A1 (en) Methods for wound treatment
AUPQ790900A0 (en) Treatment for scrubber effulent
AU2001285421A1 (en) Vaccine against rsv
AU2001271537A1 (en) Cough treatment
AU2001240424A1 (en) Immunization agent
GB0019728D0 (en) Novel treatment